Dexcom continues push into AI
Dexcom, a continuous glucose monitoring (CGM) company founded in 1999, continues to battle for the top spot in their industry. While Dexcom was the first company to receive FDA approval for CGM, and CGM continues to provide the company with over $1 billion a year in revenue, they face heavy competition from medical device giants Medtronic and Abbott. Dexcom has always had an aggressive patent prosecution strategy – the company has hundreds of applications to its name, the company has recently shifted to apply AI to their devices, as demonstrated by their portfolio. Since 2017, the company has 12 applications in the AI biotech sector, likely in an effort to stay competitive and on the cutting edge with these larger companies. Will we see their competitors follow suit?
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…